207_Combined course Presentations

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment

Osimertinib (AstraZeneca ) is a potent, irreversible EGFR tyrosine kinase inhibitor that is selective for EGFR tyrosine kinase inhibitor–sensitizing mutations and the T790M resistance mutation with an excellent therapeutic index because its activity is poor towards the wild-type EGFR

Olmutinib (HM 61713)(Boehringer Ingelheim) is an irreversible tyrosine-kinase inhibitor, selective for mutant EGFR. Its molecule structure contains a Michael acceptor that covalently binds a cysteine residue near the kinase domain of mutant EGFR

Pharmacological Research 117 (2017) 406–415